Table 1.
Baseline characteristics of 46 patients treated with fruquintinib.
| Characteristics | Number |
|---|---|
| Age (years) | |
| <60 | 25 (54.3) |
| ≥60 | 21 (45.7) |
| Gender | |
| Male | 28 (60.9) |
| Female | 18 (39.1) |
| ECOG PS | |
| 0–1 | 42 (91.3) |
| 2 | 4 (8.7) |
| Primary site | |
| Colon | 33 (71.7) |
| Rectum | 8 (17.4) |
| Unknown | 5 (10.9) |
| Metastatic organs | |
| 1–2 | 19 (41.3) |
| ≥3 | 27 (58.7) |
| RAS mutant | |
| Yes | 25 (54.3) |
| No | 12 (26.1) |
| Unknown | 9 (19.6) |
| Lines of previous therapy | |
| 2 | 33 (71.7) |
| ≥3 | 13 (28.3) |
| Previous anti-tumor agents | |
| Fluoropyromidine | 45 (97.8) |
| Irinotecan | 42 (91.3) |
| Oxaliplatin | 43 (93.5) |
| Bevacizumab | 38 (82.6) |
| Cetuximab | 13 (28.3) |
| Anti-VEGFR | 14 (30.4) |
VEGFR, vascular endothelial growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group performance status.